Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study

Sigrun Thorsteinsdottir, Paul W. Dickman, Ola Landgren, Cecilie Blimark, Malin Hultcrantz, Ingemar Turesson, Magnus Björkholm, and Sigurdur Y. Kristinsson

Disclosures: None of the authors received support for the work under consideration for publication. Support received for work outside the submitted work: Ola Landgren - consulting/advisory role for Bristol-Myers, Celgene and Onyx. Research funding from Amgen. Honoraria from Celgene, Bristol-Myers, Onyx, Medscape, Amgen Magnus Björkholm - consulting/advisory role for Roche, Janssen Cilag, Celgene, MSD and Otsuka. Cecile Blimark - advisory board for Takeda, Janssen, Celgene and Amgen. Honoraria from Grifols, Amgen, Takeda, Mundifarma and Janssen. All other authors have no disclosures.

Contributions: SYK, PD and ST designed the study. PD performed statistical analysis. SYK, OL, CHB, MB, MH and IT performed collection and assembly of data. All authors contributed to interpretation of the data. ST and SYK wrote the manuscript. All authors approved the final version of the manuscript. SYK supervised the study.